'Go Go Go:' Bankers Are Telling Startups to Get Their IPOs Done Fast

Following a market rebound after recent tariff rollbacks, companies like Chime and Hinge Health are reviving IPO plans, with bankers urging them to capitalize on the improved stability. The VIX index has dropped from a high of 52 to 17, signaling calmer markets and encouraging investors to consider new buys; however, political volatility remains a concern, and some companies, such as Klarna and StubHub, remain on the sidelines, adopting a 'wait and see' approach amid ongoing uncertainties.

Analysis

The IPO market has experienced a significant resurgence following a period of market duress initiated by President Trump's tariff announcements in early April. This recovery is evidenced by the S&P 500's approximate 19% rebound from its April lows, now trading up about 1% year-to-date, and a substantial decrease in the VIX volatility index from a peak of 52 on April 8 to 17. Consequently, companies such as digital banking app Chime and physical therapy startup Hinge Health have resumed their previously delayed IPO plans, with Hinge Health targeting a valuation up to $2.6 billion. Investment bankers, including those from Barclays and Jefferies, are actively encouraging IPO hopefuls to capitalize on this current window of stability, citing robust investor appetite and improved conditions for price agreement, as exemplified by eToro's recent successful SPAC debut which saw its shares open 34% above the IPO price. However, this optimism, reflected in a cautiously optimistic market sentiment score of 0.3, is tempered by expectations of sustained political volatility. Notably, some firms like Klarna, StubHub, and Medline—the latter significantly exposed to ongoing U.S.-China trade tensions with a 30% tariff on many of its Chinese-manufactured supplies—have not yet publicly re-engaged their IPO processes. While a substantial backlog of private companies signals pent-up demand for public listings, and early exits for long-term investors in mature companies like Omada Health are attractive, the market's trajectory beyond the typical 90 to 180-day insider lock-up period remains uncertain, prompting a 'wait and see' approach, as advised by Deutsche Bank, for companies not under immediate pressure to list.

Key Decisions for Investors

• Investors should recognize the current IPO window as potentially transient, driven by a temporary market stabilization, and thus evaluate new listings with a focus on strong fundamentals and resilience to renewed volatility.
• Careful due diligence is warranted for IPO candidates regarding their exposure to geopolitical risks and trade policies, particularly for companies with significant international supply chains like Medline, which faces continued tariff challenges.
• Given the 'rush to market' sentiment and bankers advising companies to 'go when you can,' investors in newly public companies should be prepared for potential price fluctuations and monitor insider lock-up expiration dates, which could introduce selling pressure.
• For those holding private equity, this period may present a favorable exit opportunity via IPO, but the prevailing uncertainty regarding sustained market strength beyond typical lock-up periods necessitates a thorough risk assessment of holding periods post-listing.